This activity is expired and is no longer available for CME credit.


The 3D Approach to New Treatment Options for Neovascular Retinal Diseases: Drugs, Delivery, and Devices

Author(s)/Faculty: Arshad M. Khanani, MD, MA; Dante J. Pieramici, MD; Michael A. Singer, MD
Release Date: 8/24/2020Expiration Date: 8/23/2021
Credit Type: CME / ABO MOCNumber of Credits: 0
Content Type: LectureProvider:
The utilization of anti–vascular endothelial growth factor (VEGF) therapies in treatment protocols for neovascular retinal disorders has led to significant visual gains and long-term management of disease. However, there are individuals who do not respond optimally to anti-VEGF therapy, while the high frequency of injections can lead to treatment burden and subsequent lack of adherence. Novel targeted therapies and emerging drug delivery systems have the potential to enhance long-term visual acuity outcomes and overcome lack of adherence due to treatment burden when integrated into clinical practice. In this educational activity, experts in the field will summarize the long-term efficacy of current anti-VEGF treatments, assess new evidence regarding the efficacy and safety of emerging therapies that may advance the treatment of neovascular retinal diseases, and provide insight as to how these emerging advances can be safely incorporated into real-world practice.